Camurus Valuation

Q: What is the Fair Price of CAMX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CAMX (SEK646.5) is trading below our estimate of [[fair value]] (SEK2049.68)

Is CAMX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CAMX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CAMX (SEK646.5) is trading below our estimate of fair value (SEK2049.68)

Significantly Below Fair Value: CAMX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CAMX?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for CAMX. This is calculated by dividing CAMX's market cap by their current preferred multiple.
What is CAMX's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	SEK 37.91b

CAMX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	22.2x
Enterprise Value/EBITDA	142.8x
PEG Ratio	2.3x

Price to Sales Ratio vs Peers

How does CAMX's PS Ratio compare to its peers?

The above table shows the PS ratio for CAMX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7.3x
SECARE Swedencare	2.9x	11.3%	SEK 7.1b
CALTX Calliditas Therapeutics	8.5x	29.7%	SEK 11.1b
VITR Vitrolife	8.6x	7.8%	SEK 30.3b
CLBIO Corline Biomedical	9.3x	68.2%	SEK 285.8m
CAMX Camurus	23.8x	41.3%	SEK 37.9b

Price-To-Sales vs Peers: CAMX is expensive based on its Price-To-Sales Ratio (23.8x) compared to the peer average (7.3x).

Price to Earnings Ratio vs Industry

How does CAMX's PE Ratio compare vs other companies in the SE Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	66.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	66.8%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: CAMX is expensive based on its Price-To-Sales Ratio (23.8x) compared to the Swedish Pharmaceuticals industry average (15.4x).

Price to Sales Ratio vs Fair Ratio

What is CAMX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CAMX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	23.8x
Fair PS Ratio	25.3x

Price-To-Sales vs Fair Ratio: CAMX is good value based on its Price-To-Sales Ratio (23.8x) compared to the estimated Fair Price-To-Sales Ratio (25.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CAMX forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	SEK 646.50	SEK 742.67 +14.9%	2.8%	SEK 770.00	SEK 710.00	n/a	6
Jul ’25	SEK 594.00	SEK 621.50 +4.6%	9.4%	SEK 690.00	SEK 500.00	n/a	6
Jun ’25	SEK 581.00	SEK 612.33 +5.4%	12.7%	SEK 690.00	SEK 445.00	n/a	6
May ’25	SEK 498.20	SEK 577.17 +15.9%	14.4%	SEK 690.00	SEK 445.00	n/a	6
Apr ’25	SEK 507.50	SEK 577.17 +13.7%	14.4%	SEK 690.00	SEK 445.00	n/a	6
Mar ’25	SEK 468.80	SEK 573.00 +22.2%	15.7%	SEK 690.00	SEK 420.00	n/a	6
Feb ’25	SEK 523.50	SEK 549.83 +5.0%	20.8%	SEK 690.00	SEK 420.00	n/a	6
Jan ’25	SEK 538.00	SEK 508.00 -5.6%	19.8%	SEK 650.00	SEK 420.00	n/a	6
Dec ’24	SEK 472.60	SEK 471.33 -0.3%	17.3%	SEK 650.00	SEK 420.00	n/a	6
Nov ’24	SEK 339.00	SEK 351.33 +3.6%	6.7%	SEK 380.00	SEK 320.00	n/a	6
Oct ’24	SEK 310.80	SEK 320.50 +3.1%	17.4%	SEK 380.00	SEK 205.00	n/a	6
Sep ’24	SEK 299.40	SEK 320.50 +7.0%	17.4%	SEK 380.00	SEK 205.00	n/a	6
Aug ’24	SEK 294.00	SEK 320.50 +9.0%	17.4%	SEK 380.00	SEK 205.00	SEK 681.00	6
Jul ’24	SEK 278.60	SEK 298.17 +7.0%	14.4%	SEK 332.00	SEK 205.00	SEK 594.00	6
Jun ’24	SEK 277.80	SEK 298.17 +7.3%	14.4%	SEK 332.00	SEK 205.00	SEK 581.00	6
May ’24	SEK 233.20	SEK 284.67 +22.1%	14.1%	SEK 320.00	SEK 205.00	SEK 498.20	6
Apr ’24	SEK 219.40	SEK 284.67 +29.7%	14.1%	SEK 320.00	SEK 205.00	SEK 507.50	6
Mar ’24	SEK 228.00	SEK 284.67 +24.9%	14.1%	SEK 320.00	SEK 205.00	SEK 468.80	6
Feb ’24	SEK 249.40	SEK 310.00 +24.3%	5.5%	SEK 330.00	SEK 280.00	SEK 523.50	5
Jan ’24	SEK 252.60	SEK 305.00 +20.7%	5.1%	SEK 320.00	SEK 280.00	SEK 538.00	4
Dec ’23	SEK 263.40	SEK 305.00 +15.8%	5.1%	SEK 320.00	SEK 280.00	SEK 472.60	4
Nov ’23	SEK 252.40	SEK 283.00 +12.1%	6.6%	SEK 310.00	SEK 262.00	SEK 339.00	4
Oct ’23	SEK 258.40	SEK 267.40 +3.5%	13.2%	SEK 310.00	SEK 205.00	SEK 310.80	5
Sep ’23	SEK 217.80	SEK 254.40 +16.8%	11.7%	SEK 290.00	SEK 205.00	SEK 299.40	5
Aug ’23	SEK 230.80	SEK 254.40 +10.2%	11.7%	SEK 290.00	SEK 205.00	SEK 294.00	5

Analyst Forecast: Target price is less than 20% higher than the current share price.